The granulocytes in neutropenia 1 (GIN 1) study: a safety study of granulocytes collected from whole blood and stored in additive solution and plasma

Massey, Edwin; Harding, Kay; Kahan, Brennan C; Llewelyn, Charlotte; Wynn, Robert F.; Moppett, John; Robinson, Stephen; Green, Ann; Lucas, Geoff; Sadani, Deepak; Liakopoulou, Effie; Marks, David I.; Stanworth, Simon

doi:10.1111/j.1365-3148.2012.01152.x

Cited by 31 publications

(26 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The exact role of granulocyte transfusions (whether derived from whole blood or collected by apheresis) therefore remains unclear. In the UK, a recent study reported on the safety of the use of a component derived from whole blood donations, and recruitment included 13 children (Massey et al , ). The reaction profile was similar to that with other granulocyte components and all the children recovered.…”

Section: Transfusions To Infants and Childrenmentioning

confidence: 99%

Guidelines on transfusion for fetuses, neonates and older children

et al. 2016

View full text Add to dashboard Cite

Section: Transfusions To Infants and Childrenmentioning

confidence: 99%

Guidelines on transfusion for fetuses, neonates and older children

et al. 2016

View full text Add to dashboard Cite

“…The “Granulocytes in neutropenia 1” (GIN 1) [46], a multicenter study from the U.K., evaluated the safety of transfusing pooled, whole blood-derived granulocytes. The product (“granulocytes in additive solution and plasma”: GASP) is obtained by combining 10 buffy coats (obtained from 10 blood donations) with 400 mL of platelet additive solution and re-centrifuging [25].…”

Section: Gtx For Treatment Of Infection: Review Of Recent Studies (Pomentioning

confidence: 99%

Granulocyte transfusions: A concise review for practitioners

Gea-Banacloche

2017

Cytotherapy

View full text Add to dashboard Cite

Granulocyte transfusions (GTXs) have been used to treat and prevent infections in neutropenic patients for more than 40 years, despite persistent controversy regarding their efficacy. This narrative review attempts to complement recent systematic reviews by the Cochrane Collaboration and provide both historical context and critical assessment of the most significant clinical studies published over the years. The data suggest that properly collected and promptly infused granulocytes are active against infections, both bacterial and fungal. The most important question that remains unanswered is in which patients the administration of granulocytes will be beneficial. The preponderance of evidence suggests that granulocyte transfusions may be efficacious in few select cases as a temporizing measure to control an infection that is expected (or proven) to be refractory to optimal antimicrobial treatment, and that could otherwise be controlled by marrow recovery, which is expected to happen. In this regard, they are best considered a “bridge” that grants enough time for the recipient to develop their own response to the infection. The challenges to use GTXs successfully are both clinical, in terms of timely identifying the patients who may benefit, and logistical, in terms of optimal selection of donors and collection technique.

show abstract

“…The EFS is considering preparing granulocytes from whole blood granulocytes as prepared by the NHSBT in England. Regulatory approval for such a blood product will be requested by the end of 2017.…”

Section: Francementioning

confidence: 99%

Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use

et al. 2017

View full text Add to dashboard Cite

Question 1 (a) We have local institutional guidelines to cover the use of therapeutic granulocyte infusions. The petermac site does not use prophylactic granulocytes, but our sister site with whom we are merging this year has used them on a couple of occasions.Question 2 (a) yes (b) Usage is increasing over time due to recognition of benefit, availability of a pool granulocyte product to intervene while donor granulocytes are organised

show abstract

The granulocytes in neutropenia 1 (GIN 1) study: a safety study of granulocytes collected from whole blood and stored in additive solution and plasma

Abstract: GASP has a similar safety profile to other sources of granulocytes for patients with refractory infection or in need of secondary prophylactic transfusion. Further studies are required to clarify the role of GASP in the treatment of neutropenic patients.

Cited by 31 publications

References 39 publications

Guidelines on transfusion for fetuses, neonates and older children

Guidelines on transfusion for fetuses, neonates and older children

Granulocyte transfusions: A concise review for practitioners

Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use

Contact Info

Product

Resources

About